Ben Zeskind
Co-founder and CEO of Immuneering focused on developing a new class of cancer therapies called deep cyclic inhibitors; discusses clinical data and company strategy for pancreatic and other cancers.
Best podcasts with Ben Zeskind
Ranked by the Snipd community
Mar 20, 2026 • 32min
How Immuneering’s Journey Highlights Biotech’s Market Complexity
Ben Zeskind, Co-founder and CEO of Immuneering, leads development of deep cyclic inhibitors for durable, better‑tolerated cancer treatments. He discusses striking phase 2 pancreatic survival results, how the drugs target cancer’s escape mechanisms, quality‑of‑life benefits, company strategy from research to IPO, and why markets often miss durable, long‑term approaches in biotech.
